Should a patient with coronary artery disease status post coronary stent who is taking aspirin (acetylsalicylic acid) hold the aspirin for seven days before undergoing a diagnostic bilateral L3–L4 dorsal ramus medial branch block?

Should Aspirin Be Held for 7 Days Before Diagnostic L3-L4 Medial Branch Block in a Post-Stent CAD Patient?

No, aspirin should NOT be held for 7 days before a diagnostic bilateral L3-L4 dorsal ramus medial branch block in this patient with coronary artery disease status post stent placement. The procedure should proceed with aspirin continued, as the bleeding risk of this diagnostic spinal injection is low to intermediate, while the thrombotic risk of aspirin discontinuation in a post-stent patient is potentially catastrophic.

Risk Stratification Framework

Hemorrhagic Risk of the Procedure

A diagnostic bilateral L3-L4 dorsal ramus medial branch block represents a low to intermediate hemorrhagic risk procedure 1. This is not a major hemorrhagic risk procedure like neurosurgery, major tissue detachment surgery, or posterior segment eye surgery 1. The French Task Force specifically categorizes procedures as:

• Major risk: Intervention cannot proceed on antiplatelet agents
• Intermediate risk: Intervention can proceed on aspirin alone
• Minor risk: Intervention can proceed on dual antiplatelet therapy 1

Diagnostic spinal injections fall into the intermediate category at most, meaning they can safely proceed with aspirin monotherapy 2.

Thrombotic Risk Assessment

The patient's thrombotic risk depends critically on:

• Time since stent placement: The date provided indicates this is likely a remote stent (>6-12 months post-placement)
• Type of stent: Drug-eluting stent (DES) vs bare-metal stent (BMS)
• Indication for stenting: Acute coronary syndrome vs stable CAD
• High-risk features: Multiple stents, bifurcation lesions, diabetes, low ejection fraction 1

Evidence-Based Recommendation

Continue Aspirin Throughout the Procedure

Aspirin should be maintained perioperatively for the following compelling reasons:

• Guideline consensus: Multiple high-quality guidelines uniformly recommend continuing aspirin for procedures with low to intermediate bleeding risk 1. The French Task Force explicitly states that "maintaining aspirin during surgery was the preferred option" in patients with coronary stents, irrespective of when the stent was placed 1.

• Post-stent patients require lifelong aspirin: The 2024 ESC Guidelines recommend aspirin 75-100 mg daily lifelong in patients with prior MI or revascularization 3. The 2014 ACC/AHA perioperative guidelines state it is reasonable to continue aspirin when the risk of cardiac events outweighs bleeding risk 4.

• Aspirin withdrawal is dangerous: Aspirin discontinuation in coronary disease patients carries significant risk of acute coronary events, including late stent thrombosis 5. The mean delay between aspirin withdrawal and acute coronary events is approximately 10 days, with 20% involving late stent thrombosis 5.

• Bleeding risk is manageable: The 2024 AHA/ACC perioperative guidelines recommend continuing aspirin (75-100 mg) if possible during noncardiac surgery to reduce cardiac events 6. The bleeding risk of continuing low-dose aspirin for spinal procedures is substantially lower than the thrombotic risk of discontinuation 2.

Critical Timing Considerations

If this patient's stent was placed:

• <6 months ago (especially <3 months): The procedure should ideally be postponed if possible, as this represents the highest risk period for stent thrombosis 1, 6. If the procedure cannot be deferred, aspirin must absolutely be continued 6.

• >6-12 months ago: Aspirin should still be continued, but the thrombotic risk is lower than in the early post-stent period 1.

Multidisciplinary Discussion

While aspirin continuation is strongly recommended, the French Task Force guidelines emphasize that a multidisciplinary team meeting should occur for patients with coronary stents undergoing procedures 1. This meeting should include:

• The cardiologist (to assess stent thrombosis risk)
• The interventional pain physician (to assess bleeding risk)
• The patient (to provide informed consent)

The team should document their decision regarding the balance of thrombotic versus bleeding risk 1.

Common Pitfalls to Avoid

• Do not hold aspirin for 7 days: This duration of discontinuation significantly increases thrombotic risk without meaningful reduction in bleeding risk for this procedure type 1, 5.

• Do not confuse diagnostic with therapeutic procedures: Therapeutic spinal procedures (e.g., radiofrequency ablation) may carry higher bleeding risk than diagnostic blocks 2.

• Do not assume all spinal procedures are high-risk: Superficial and deep nerve blocks performed with ultrasound guidance by experienced operators can often proceed safely on antiplatelet therapy 2.

• Verify the exact stent timing: If the stent was placed within the past 3-6 months, strongly consider postponing the elective diagnostic procedure 1, 6.

Alternative Antiplatelet Management

If the patient were on dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor):

• Aspirin should be maintained 1
• The P2Y12 inhibitor could be held for 5 days (clopidogrel, ticagrelor) or 7 days (prasugrel) if necessary 1, 2
• This strategy preserves some antiplatelet protection while reducing bleeding risk 1

However, since this patient is only on aspirin monotherapy, there is no justification for discontinuation 3, 7, 4, 6.